

# Trade Associations and Collusion on Minimum Price: Evidence from Physicians

**Jorge Alé-Chilet**    **Juan Pablo Atal**

Bar Ilan

Penn

January 2020

# Motivation

Collusion is increasingly difficult as number of firms increases (Tirole 1988, etc.)

Many *documented* cartel cases with large number of firms ( $N > 7$  in roughly 50% of cases reviewed by Levenstein and Suslow, JEL 2006).

How?

In practice, through trade associations (prevalent in many professions; e.g., engineering, law, medicine, etc.)

## Motivation (cont'd)

Ambivalent role of trade associations

Information exchanges and standard setters

But... anticompetitive concern: Can facilitate coordination on prices, establish barriers to entry, or others that diminish competition (FTC, 2018).

Such anticompetitive agreements not binding: not clear why agents should comply.

# Trade Associations and Collusion

More than 35 FTC complaints against physicians associations since 2001.

On the other hand, some antitrust practitioners have been calling to allow associations that seek to counteract large imbalances of power in negotiations (e.g., Australia's ACCC, UK's CMA)

Hotels vs. Expedia, Booking.com

Truck owners vs. transport companies

Texas, NJ, Alaska have all passed bills allowing physicians to negotiate collectively.

Question: Do trade associations lead to collusive agreements or collusive behavior?

## Colluding Physicians

*The Federal Trade Commission today announced its decision to challenge the conduct of several organizations representing more than **2,900 independent Chicago-area physicians for agreeing to fix prices** and for refusing to deal with certain health plans except on collectively determined terms. (...) The complaint also alleges that in 2001, AHP [Advocate Health Partners] **terminated its members' contracts** with a health plan that rejected contract proposals for higher fees, and threatened that it would not contract with the plan for hospital services unless it stopped contracting with individual physicians and agreed to a group contract. The resulting contract included **fees 20 percent to 30 percent higher** than the health plan's individual physician contracts.*

*"FTC Charges Chicago-Area Doctor Groups With Price Fixing."  
FTC, Press Release, December 29, 2006.*

# This Paper

We study the coordinated strategies of a large number of physicians, who were able to collude through a trade association.

Research question: What was the role of the trade association (strategies) in facilitating collusion?

Main contribution: Empirical analysis of a collusive agreement of a large cartel.

Leverage detailed data on prices, physician visits, and court documents to:

- Rationalize the Association's profitability and stability

- Provide empirical support for the theoretical predictions of collusion among heterogeneous firms (Harrington, 2016).

- Insights for antitrust policy in the context of bargaining.

# This Paper

We study the coordinated strategies of a large number of physicians, who were able to collude through a trade association.

Research question: What was the role of the trade association (strategies) in facilitating collusion?

Main contribution: Empirical analysis of a collusive agreement of a large cartel.

Leverage detailed data on prices, physician visits, and court documents to:

- Rationalize the Association's profitability and stability

- Provide empirical support for the theoretical predictions of collusion among heterogeneous firms (Harrington, 2016).

- Insights for antitrust policy in the context of bargaining.

# This Paper: Overview

**The case:** Collusion of large number ( $N = 25$ ) physicians (Ob/Gyn's) through trade association in a small city in Chile.

Break in negotiations between physicians and insurance companies. )

1. **Joint contract termination**
2. **Minimum price agreement.**

Rates increased 80%, copays 200%.

Goal: Understand Association strategies

Empirical Strategy:

1. Estimate demand for doctor's visits
2. Supply model to estimate the degree of price coordination and rationalize minimum price
3. Analyze cartel stability



# This Paper: Overview

**The case:** Collusion of large number ( $N = 25$ ) physicians (Ob/Gyn's) through trade association in a small city in Chile.

Break in negotiations between physicians and insurance companies. )

1. **Joint contract termination**
2. **Minimum price agreement.**

Rates increased 80%, copays 200%.


Goal: Understand Association strategies

Empirical Strategy:

1. Estimate demand for doctor's visits
2. Supply model to estimate the degree of price coordination and rationalize minimum price
3. Analyze cartel stability

# Main Results


**Figure:** Simulated and Actual Prices



Note: The Figure shows the average price, and the Fonasa (public) rate.

# Main Findings

**Figure: Simulated and Actual Prices**



Note: The Figure shows the Nash prices for out-of-network coinsurance rates, the average price, and the Fonasa (public) rate.

# Main Results

1. Average “Collusive” Price = Average Nash-Bertrand
2. Minimum price was binding only for a few physicians
3. Association was incentive compatible and highly profitable

## Main implications:

Collusion most effective on the decision to become out-network.

Trade association provided physicians with better option than bargained prices.

# Contribution

## Collusion

Porter (1983), Levenstein (1997), Genesove and Mullin (1998, 2001), Asker (2010), Clark and Houde (2013), Igami and Sugaya (2017), and Alé-Chilet (2018)

Methodology: Bresnahan (1987), Nevo (2001), Miller and Weinberg (2017)

## Anticompetitive Effects of Trade Associations

Large N: Symeonidis (2002), Levenstein and Suslow (2006, 2011)

Unions: Gu and Kuhn (1998), and Cramton and Tracy (2003)

## Negotiation in Vertical Markets

Ho and Lee (2017)

Bargaining goal of horizontal agreements in vertical markets, e.g., mergers: Grennan (2013), Gowrisankaran, Nevo, and Town (2015).

# Road Map

1. The Antitrust Case
2. Data
3. Demand Estimation
4. Supply Model
5. Association Stability

# Institutional Details

## Insurance Coverage in Chile

### **Private Insurance - 20%:**

6 Insurance companies.

Thousands of plans; different network, different coverage for in-network and out-of-network (i.e., mostly "PPO" structure).

In-network providers negotiate their rates with insurance companies.

Out-of-network providers set their rates privately.

### **Public Insurance - 80%: (Fonasa)**

Reimburses (private and public) providers with a common rate.


Setting: Chillán, Chile: city of 175,000 inhabitants in southern Chile. 28 Ob/Gyns in the city. 25 formed the trade association.

Many things to do in Chillan besides going to the doctor





# The Case



# Data

Source: National Economic Prosecutor's Office

Insurer records + doctor records,

2009m1-2013m1; Chillan + Neighboring Cities

Individual claims with doctor id, patient id, type of claim, total price, out-of-pocket expenditure.

Keep *visits* only

Aggregate data at physician/insurer/month level

Each insurer/month is a "market"

## Figure: Prices and Coinsurance rates over time

(a) Average Visit Price

(b) Average Coinsurance Rate

Note: The Figure shows the median visit price and coinsurance rate faced by patients of the average gynecologists in Chillan and in two other major neighboring cities (Concepción and Los Angeles). Prices are in Chilean Pesos (approximately CLP 500 = USD 1).

## Figure: Histogram of Median Prices

(a) Pre-Association

(b) Association

Note: The Figure shows the distribution of the median price across Chillan gynecologists in the period before and after collusion (2011 and 2012). We drop prices in the transition month of January 2012. Prices are in Chilean Pesos (approximately CLP 500 = USD 1). The dashed line is the rate paid by the public insurance (Fonasa) and the dotted line is the minimum price set by the TA.

## Figure: Average Number of Visits and Profits over Time

Note: The Figure shows the average number of visits and profits (using Fonasa as the cost) for associated and not associated physicians.

## Figure: Did Patients or Insurers Lose?

Note: The Figure shows the aggregated expenses of patients and insurers due to physicians visits.

# Road Map

1. The Antitrust Case
2. Data
3. Demand Estimation
4. Supply Model
5. Association Stability

# Demand Estimation

## Reduced Form Evidence

Evidence of large demand responses.

We look at switching rates of patients across doctors.



## Figure: Physician switching rates in Nuble and surrounding provinces

Note: The figure shows the average switching rates across doctors for OBGYN visits in the province of Nuble (where collusion occurred) and in surrounding provinces (Biobo and Concepción). The vertical line marks the date of the collusion.

# Demand Estimation

## Structural Model

Demand model in a nutshell:

Nested logit model. Define nests based on the doctor's geographic location

Instrument for price and within-share:

$$Z_{it} = (\text{Association}_{it}; \text{Association}_{it} \text{ Post}_{it})$$

Many zero-shares:

Logit models do not handle zero shares (censoring). Empirical Bayesian estimator of the choice probabilities (Gandhi et al., 2014).

## Nested Logit

The set of physicians is partitioned into non-overlapping nests,  $1, \dots, K$ .

Nests allows for higher correlations  $\rho$  within predetermined groups

Indirect utility of patient  $p$  enrolled in  $j$  from visiting doctor  $i$  in nest  $k$  is

$$u_{pijt} = d_{ijt} + e_{ijt} + h_{pkjt} + (1 - s) \eta_{pijt},$$

where

$$d_{ijt} = \alpha p_{ij} (1 - c_{ijt}) + m_j + f(t).$$

$p_{ij}$  is the list price,  $1 - c_{ijt}$  is the coinsurance rate,  $m_j$  represent F.E's for doctor-insurer pairs,  $f(t)$  represent time controls (common shocks); and

$$h_{pkjt} + (1 - s) \eta_{pijt} \sim EV(1)$$

## Estimation: Locations and Nests

Note: The Figure plots the geographic location of physician's main address. Each color represents a different nest. Large circles represent groups of five or more co-located physicians. Small dots represent groups of three or less physicians.

# Estimation Challenges

Using Berry's (1994) inversion, can estimate model from

$$\ln(s_{ijt}) - \ln(s_{0jt}) = \alpha p_{ijt} (1 - \gamma_{ijt}) + m_{i,j} + f(t) + s \ln(s_{ijt} / B_k) + e_{ijt}$$

where  $\alpha$  measures price sensitivity, within nest substitutability.

## Endogeneity

Leverage price shock brought about by Association; IV for price and within-share  $Z_{it} = (\text{Post}_t; \text{Association} \cdot \text{Post}_t)$

## Zero-shares

Large number (26%) of zeros of physician-insurer-month observations (dataset is of private patients)

Empirical Bayesian estimator of the choice probabilities.

# Estimation Challenges

Using Berry's (1994) inversion, can estimate model from

$$\ln(s_{ijt}) - \ln(s_{0jt}) = \alpha p_{ijt} (1 - \sigma_{ijt}) + m_{i,j} + f(t) + s \ln(s_{ijt} / B_k) + e_{ijt}$$

where  $\alpha$  measures price sensitivity, within nest substitutability.

## Endogeneity

Leverage price shock brought about by Association; IV for price and within-share  $Z_{it} = (\text{Post}_t; \text{Association}_i - \text{Post}_t)$

## Zero-shares

Large number (26%) of zeros of physician-insurer-month observations (dataset is of private patients)

Empirical Bayesian estimator of the choice probabilities.

# Estimation Challenges

Using Berry's (1994) inversion, can estimate model from

$$\ln(s_{ijt}) - \ln(s_{0jt}) = \alpha p_{ijt} (1 - \sigma_{ijt}) + m_{i,j} + f(t) + s \ln(s_{ijt} / B_k) + e_{ijt}$$

where  $\alpha$  measures price sensitivity, within nest substitutability.

## Endogeneity

Leverage price shock brought about by Association; IV for price and within-share  $Z_{it} = (\text{Post}_t; \text{Association}_i - \text{Post}_t)$

## Zero-shares

Large number (26%) of zeros of physician-insurer-month observations (dataset is of private patients)

Empirical Bayesian estimator of the choice probabilities.

Table: Demand Estimates

	(1)	(2)	(3)	(4)
	Logit OLS	Logit IV	NL OLS	NL IV
$p_{ijt} (1 \quad c_{ijt})$	0.004 (0.010)	-0.146*** (0.017)	0.004 (0.004)	-0.050*** (0.018)
In within-share			1.040*** (0.005)	0.735*** (0.152)
$h_{pre}$	0.02	-0.60	-0.29	-0.65
$h_{post}$	0.04	-1.53	-0.75	-1.68
Observations	6620	6620	6620	6620
AR F-stat		39.42		39.42
AP F-stat 1		1899.99		334.84
AP F-stat 2				19.83

Note: All specifications include month-of-the-year and year fixed effects. Expenditures are in thousand CLP. The AR F-stat corresponds to the Anderson-Rubin Wald F-statistic. The AP F-stat 1 and 2 correspond to the first-stage F statistics of the excluded instrument. \*  $p < 0.1$ , \*\*  $p < 0.05$ , \*\*\*  $p < 0.01$



# Road Map

1. The Antitrust Case
2. Data
3. Demand Estimation
4. Supply Model
5. Association Stability

# Supply Model

Model allows to calculate equilibrium prices for any level of collusion.  
 Colluding physician decides a unique list price, for all (J) insurance companies, results in price vector and sales,  $j = 1..J$  (omitting t).

FOC (Nevo, 1998, 2001; Miller and Weinberg, 2017):

$$p - mc = W(k) \sum_j \tilde{S}_j \frac{\partial q_j(p, c_j)}{\partial p}$$

Where

$W(k)$  matrix with diagonal elements 1, non-diagonal elements  $k$ . Nests Nash-Bertrand competition when  $k=0$ ; full collusion when  $k = 1$ .

$\tilde{S}_j = E_j \tilde{C}_j$ , matrix of price sensitivity  $1 - \text{coverage}$ .

$E_j(r, s) = \frac{\partial q_{sj}}{\partial p_r}$  matrix of derivatives wrt out-of-pocket prices,  $\tilde{C}_j(r, s) = 1 - c_{rj}$ .

Assumption:  $mc$  is equal to the public rate: opportunity cost of a visit.

Arguably lower bound; but close to pre-agreement price (upper bound).

# Main Results

Figure: Simulated and Actual Prices

Note: The Figure shows the average price, and the Fonasa (public) rate.

# Main Findings

Figure: Simulated and Actual Prices

Note: The Figure shows the Nash prices for out-of-network coinsurance rates, the average price, and the Fonasa (public) rate.

## Figure: Distribution of Nash-Bertrand Prices

Note: The Figure plots the histogram of the estimated Nash prices of each associated physician, averaged over the Association period. The dashed line shows the Association's minimum price.

## Main Results: Price Level

Average Nash-Bertrand price (CLP 26,800) is  
almost equal to average observed price set by Association members.

The distribution of the Nash-Bertrand prices is such that the minimum price barely binds (min NASH = min price)

Collusive price ( $\kappa = 1$ ) is equal to CLP 52,336; 2x the average observed price

## Figure: Predicted v/s Actual Price as a function of $\alpha$

Note: The Figure shows the ratio between the sales-weighted average price predicted by the supply model and the sales-weighted average observed price in the post-association period.

# Implications

Collusion mainly on the decision to become out-of-network. Minimum price did not bind.

Association pricing was competitive, but no longer constrained by insurers.

Trade association served to move to a different equilibrium from bargaining providing physicians with a better option than the pre-association one.

Minimum price served as competitive "focal price"

Harrington (2016): Minimum price preserves heterogeneity, incentive compatible.



# Road Map

1. The Antitrust Case
2. Data
3. Demand Estimation
4. Supply Model
5. Association Stability

# Counterfactuals

## The stability and the role of the Association

Stability . We compare profits under:

I Association

Nash Prices, out-of-network coinsurance

II Unilateral Deviation from Association

Deviation to pre-association price and in-network coinsurance

The role of the Association . We compare profits under:

I Unilateral Contract Termination

Out-of-network profit maximizing price given all others in-network

II Joint Contract Termination

out-of-network Nash, others in out-network Nash.

III No Association

In-network prices and coinsurance rates.

# Counterfactuals

## The stability and the role of the Association

Stability . We compare profits under:

I Association

Nash Prices, out-of-network coinsurance

II Unilateral Deviation from Association

Deviation to pre-association price and in-network coinsurance

The role of the Association . We compare profits under:

I Unilateral Contract Termination

Out-of-network profit maximizing price given all others in-network

II Joint Contract Termination

out-of-network Nash, others in out-network Nash.

III No Association

In-network prices and coinsurance rates.

# Assessing the Cartel's Stability

Counterfactual: unilateral deviation from the agreement

"Deviation": Pre-agreement list price ( $p_i^d$ ) instead of Nash ( $p_i^N$ ) and in-network coinsurance rate ( $c_{i,j}^I$ ) instead of out-of-network ( $c_{i,j}^O$ )

Compute deviation profits:

$$\begin{aligned}
 p_i^d - p_i^N &= p(p_i^d, p_i^N, c_{i,j}^I, c_{i,j}^O) - p(p_i^N, p_i^N, c_{i,j}^O, c_{i,j}^O) \\
 &= \underbrace{p(p_i^d, p_i^N, c_{i,j}^O, c_{i,j}^O)}_{\text{out-of-ntwk price deviation} < 0} - \underbrace{p(p_i^N, p_i^N, c_{i,j}^O, c_{i,j}^O)}_{\text{higher sales from higher coverage} > 0} + \\
 &\quad \underbrace{p(p_i^d, p_i^N, c_{i,j}^I, c_{i,j}^O)}_{\text{higher sales from higher coverage} > 0} - \underbrace{p(p_i^d, p_i^N, c_{i,j}^O, c_{i,j}^O)}_{\text{out-of-ntwk price deviation} < 0}
 \end{aligned}$$

Sign is ambiguous: empirical question.

Robust to re-estimating  $p_i^N$  given  $i$ 's deviation.

# Assessing the Cartel's Stability

Counterfactual: unilateral deviation from the agreement

"Deviation": Pre-agreement list price ( $p_i^d$ ) instead of Nash ( $p_i^N$ ) and in-network coinsurance rate ( $c_{i,j}^I$ ) instead of out-of-network ( $c_{i,j}^O$ )

Compute deviation profits:

$$\begin{aligned}
 p_i^d - p_i^N &= p(p_i^d, p_i^N, c_{i,j}^I, c_{i,j}^O) - p(p_i^N, p_i^N, c_{i,j}^O, c_{i,j}^O) \\
 &= \underbrace{p(p_i^d, p_i^N, c_{i,j}^O, c_{i,j}^O)}_{\text{out-of-ntwk price deviation} < 0} - \underbrace{p(p_i^N, p_i^N, c_{i,j}^O, c_{i,j}^O)}_{\text{higher sales from higher coverage} > 0} + \\
 &\quad \underbrace{p(p_i^d, p_i^N, c_{i,j}^I, c_{i,j}^O)}_{\text{higher sales from higher coverage} > 0} - \underbrace{p(p_i^N, p_i^N, c_{i,j}^O, c_{i,j}^O)}_{\text{higher sales from higher coverage} > 0}
 \end{aligned}$$

Sign is ambiguous: empirical question.

Robust to re-estimating  $p_i^N$  given  $i$ 's deviation.

# Counterfactual I: Stability

Figure: Unilateral Deviation Profits;  $\frac{p^d}{p^N} p^N$

(a) Deviation Profits; Step 1

(b) Deviation Profits; Step 2

Note: The Figure shows the distribution of per-period deviation profits across physicians. Each point in the figure corresponds to the deviation profit of a different physician, as a percentage of the profit from staying in the Association.

# Counterfactuals

## The stability and the role of the Association

Stability . We compare profits under:

I Association

Nash Prices, out-of-network coinsurance

II Unilateral Deviation from Association

Deviation to pre-association price and in-network coinsurance

The role of the Association . We compare profits under:

I Unilateral Contract Termination

Out-of-network profit maximizing price given all others in-network

II Joint Contract Termination

out-of-network Nash, others in out-network Nash.

III No Association

In-network prices and coinsurance rates.

## Counterfactual II: The role of the association

Figure: Termination Profits as a Share of In-network Profits

Note: The Figure plots the gains from leaving the network if all doctors of the Association leave the network (Joint Termination) and if only the focal doctor becomes out-of-network (Unilateral Termination). Baseline profits correspond to all doctors staying in-network.



## Counterfactual II: The role of the association

Unilateral deviation did not happen. This is consistent with the physicians' goal to reach (ultimately) better terms with the insurers.

Coordinated action was used to increase the physicians' bargaining position which raised their outside option to the point where the negotiation broke down.

These facts show that coordination/communication played an important role in the breakdown of negotiations.

## Summary and Discussion

We empirically study a case of a collusive agreement among large number agents through a trade association.

Coordination on minimum price and on joint contract termination, but did not achieve supra-competitive prices.

Highly successful (increased profits) and stable.

## Summary and Discussion (cont'd)

### Antitrust implications

Difference between economic collusion and illegal anticompetitive practices (e.g., minimum price).

Role of communication: despite sustained coordination, association did not raise prices above competitive levels.

Find Association more effective on joint contract termination.

Maybe different nature makes it easier to coordinate in variables other than price.

Joint bargaining. Role of antitrust policy in horizontal coordination with vertical agreements.

Trade associations and collusion? Not economic collusion, but consumers definitely worse off.

THANKS

## Figure: Changes in Visits and Changes in Out-of-Pocket Prices

Note: The Figure plots the percentage changes in out-of-pocket prices against percentage changes in visits in 2012 with respect to 2011 for every physician, and a linear fit. The size of the markers correspond to the physician's total number of visits in the period, which are also the linear fit weights.

# Switching Rates

For patient  $p$  in province  $l$  and period  $t$ , we estimate the di-in-di s model:

$$w_{plt} = a_t + bT_l + dAfter_t + gT_l \text{ After}_t + I_t + \epsilon_{plt}$$

where  $w$  is a switch indicator,  $T_l$  is a Nuble indicator,  $I_t$  are time controls. The parameter  $g$  is the estimated effect of the collusion on switching rates Nuble.

Table: Physician switching rates

	(1)	(2)
$T_1 = 1$	0.08*** (0.01)	0.08*** (0.01)
After <sub>t</sub>	0.03*** (0.01)	
(After <sub>t</sub> ) $T_1$	0.07*** (0.02)	0.07*** (0.02)
Year-month FE	N	Y
N	16,742	16,742
R <sup>2</sup>	0.02	0.02
Baseline switching	0.22	0.22

Note: The baseline switching rate corresponds to the switching rate in Nuble before the agreement period. Heteroscedasticity robust standard errors in parentheses. \*  $p < 0.10$ , \*\*  $p < 0.05$ , \*\*\*  $p < 0.01$

# Capacity Constraints

No observable capacity constraints

Note: The Figure plots the distribution of the 75-99.9 percentiles of the visits per month distribution of ob/gyn in Nuble and in other neighboring provinces.



# Zero Shares

Large number (26%) of zeros of physician-insurer market shares in data.

Logit models do not handle zero shares (censoring).

Ad-hoc standard approaches: (1) drop zero sales or (2) replace with (small)  $\epsilon$ , highly sensitive.

Data-driven "optimal" transformation of empirical shares based on Gandhi et al. (2014). Empirical Bayesian estimator of the choice probabilities.

Observed shares  $s_{ijt}$  are the realization of the shares in a small-sample which differ from the true population probabilities  $p_{ijt}$  implied by the model.

Infer conditional distribution of choice probabilities given empirical shares assuming sales accord with Zipf's law.

## Zero Shares (2)

Assuming

$$(A1) \quad M_j \sim \text{MN}(p, M)$$

$$(A2) \quad \frac{p_j}{p_0} \sim \text{Dir}(q \mathbf{1}_J) \quad (\text{Zipf's law for sales})$$

Then

$$M_j \frac{s_{ijt}}{1 - s_{0jt}} \sim \text{DCM}(q \mathbf{1}_J, M_j (1 - s_{0jt})),$$

And

$$\log(\hat{p}_j) - \log(\hat{p}_0) = \psi(q + Ms_j) - \psi(Ms_0)$$

$$\log(\hat{p}_j) - \log(\hat{p}_c) = \psi(q + Ms_j) - \psi(\hat{a}_j)$$

Where  $\psi$  is the Digamma Function.

## Zero Shares (3)

1. Estimate  $q_j$  via ML.
2. Estimate

$$\begin{aligned}
 & \frac{E[\ln(s_j)]}{\ln(s_0)} \left\{ \right. \\
 & y(q_j + M_j s_{jt}) - y(M_j s_{0jt}) = \alpha_{ijjt} (1 - c_{ijjt}) + m_{j,t} + f(t) + \# \\
 & \left. \frac{y(q_j + M_j s_{ht}) - y(\hat{a} q_j + M_j s_{jt})}{E[\ln(s_j / s_j)]} + e_{ijt} \right\}
 \end{aligned}$$

Table: Nested Logit Estimates{Zero Market Shares Correction

	(1)	(2)	(3)
$P_{ijt} (1 - c_{ijt})$	-0.015 (0.011)	-0.028*** (0.008)	-0.050*** (0.018)
In within-share	1.066*** (0.148)	0.850*** (0.108)	0.735*** (0.152)
Correction	No Zeros	Ones	Dirichlet
$h_{pre}$	0.62	-0.61	-0.65
$h_{post}$	1.63	-1.58	-1.68
Observations	4870	6620	6620
AR F-stat	52.04	73.72	39.42
AP F-stat 1	329.78	429.49	334.84
AP F-stat 2	31.90	46.55	19.83

Note: All specifications include month-of-the-year and year fixed effects. Expenditures are in thousand CLP. The AR F-stat corresponds to the Anderson-Rubin Wald F-statistic. The AP F-stat 1 and 2 correspond to the first-stage F statistics of the excluded instruments. \*  $p < 0.1$ , \*\*  $p < 0.05$ , \*\*\*  $p < 0.01$

## Finding $k$

Formally, we define  $f(k)$  as

$$f(k) = \frac{1}{T} \sum_{t=t_0}^T \frac{\frac{1}{N} \sum_i a_i j^i \frac{P_{it}^N(k)}{P_{it}} j q_{ijt}(k)}{\sum_i a_i q_{ijt}(k)},$$

**Figure:** Loss Function  $k$

